A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury
(Q46869499)
scientific article published in December 2005
scientific article published in December 2005
Language:
Current Data About
A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury
other details
| description | scientific article published in December 2005 |
External Links
| (P356) |
10.1089/NEU.2005.22.1444
|
| (P698) |
16379582
|